stockrowViking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
Follow VKTX
Alert me
Viking Therapeutics, Inc. (VKTX) Operating cash flow
Viking Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$278.7M, compared with −$87.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$462.6M. Over the past ten years it has ranged from −$278.7M (fiscal 2025) to −$8.7M (fiscal 2015) — the current reading is the lowest in ten years. Operating cash flow has fallen for 5 consecutive fiscal years. Viking Therapeutics, Inc. ranks 591st of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$278.7M | — |
| FY2024 | −$87.8M | — |
| FY2023 | −$73.4M | — |
| FY2022 | −$48.4M | — |
| FY2021 | −$47.6M | — |
| FY2020 | −$21.8M | — |
| FY2019 | −$24.8M | — |
| FY2018 | −$18.8M | — |
| FY2017 | −$14.8M | — |
| FY2016 | −$11.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$138.2M | — |
| Jun 2026 | −$125.2M | — |
| Mar 2026 | −$114.0M | — |
| Dec 2025 | −$85.3M | — |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $97.5M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $49.9M |
| ELVN Enliven Therapeutics, Inc. compare | −$66.9M |
| PBLS Parabilis Medicines, Inc. compare | −$118.1M |
| CELC Celcuity, Inc. compare | −$191.7M |
| IRON Disc Medicine, Inc. compare | −$197.5M |
| XENE Xenon Pharmaceuticals Inc. compare | −$337.5M |
| VKTX Viking Therapeutics, Inc. | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$477.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item